Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Guidant/Vesalius Ventures: Telemedicine and clinical informatics "seed-stage" venture capital funding opportunities will be the primary focus of Vesalius Ventures - formed by Guidant in partnership with Vanguard Ventures and Fremont Ventures, Guidant says. The convergence of medical and information technologies "offers opportunities to more effectively diagnose and treat patients with chronic diseases," Guidant Chief Information Officer William McConnell explains in a release. Separately, Guidant invests $10 mil. in privately held Cardica, Inc., developer of automated anastomosis technology for off-pump and on-pump coronary bypass surgery...

You may also be interested in...



Nomos Goes Public Via North American Scientific Merger Valued At $56 Mil.

Radiation oncology firm North American Scientific, Inc. (NASI) will more than triple its revenue to $55-$60 mil. with the purchase of intensity modulated radiation therapy (IMRT) developer Nomos under an Oct. 27 agreement

Nomos Goes Public Via North American Scientific Merger Valued At $56 Mil.

Radiation oncology firm North American Scientific, Inc. (NASI) will more than triple its revenue to $55-$60 mil. with the purchase of intensity modulated radiation therapy (IMRT) developer Nomos under an Oct. 27 agreement

WorldHeart HeartSaver R&D Consolidation: 25% Personnel Cut Planned

WorldHeart's plan to merge the HeartSaverVAD and HeartSaverVADII development programs will save $10 mil. per year and help the firm reach profitability by 2004, the left-ventricular assist device maker predicts

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel